FDA Approves Keytruda for Adjuvant Treatment of Stage III Melanoma

Key Takeaways

• FDA approved pembrolizumab for adjuvant Stage III melanoma on February 15, 2019 (FDA announcement)
• KEYNOTE-054 trial demonstrated 43% reduced recurrence risk (HR 0.57, 95% CI 0.46-0.70, p<0.001)
• Approved for patients with lymph node involvement following complete resection
• Dosing: 200 mg IV every 3 weeks for up to 1 year or until recurrence/unacceptable toxicity

What Is Adjuvant Therapy?

Adjuvant therapy is additional treatment given after the primary treatment—usually surgery—to lower the risk of cancer recurrence. In melanoma, adjuvant therapy targets microscopic residual disease that may remain after complete surgical resection of visible tumors. The FDA approval of pembrolizumab marked the first anti-PD-1 therapy approved specifically for adjuvant melanoma treatment.

What Evidence Supported the FDA Approval?

The KEYNOTE-054 trial (EORTC1325/KEYNOTE-054, NCT02362594) provided the primary evidence. This randomized, double-blind, placebo-controlled Phase 3 study enrolled 1,019 patients with completely resected Stage IIIA (>1 mm lymph node metastasis), IIIB, or IIIC melanoma.

Key efficacy findings from the published trial results:

• Primary endpoint (recurrence-free survival): HR 0.57 (95% CI: 0.46-0.70; p<0.001)
• 3-year RFS rate: 63.7% pembrolizumab vs. 44.1% placebo
• 5-year RFS rate: 55.4% pembrolizumab vs. 38.3% placebo
• Distant metastasis-free survival: HR 0.62 (95% CI: 0.52-0.75)

How Does Keytruda Work?

Keytruda is a humanized monoclonal antibody that blocks the programmed death-1 (PD-1) immune checkpoint. By inhibiting the interaction between PD-1 receptors on T cells and PD-L1/PD-L2 ligands expressed on tumor cells, pembrolizumab restores T-cell-mediated anti-tumor immune activity. This mechanism differs from prior adjuvant melanoma therapies like interferon and ipilimumab.

What Are the Recommended Dosing and Administration Guidelines?

The FDA-approved dosing for adjuvant melanoma is:

• Dose: 200 mg administered intravenously
• Frequency: Every 3 weeks
• Duration: Up to 1 year, or until disease recurrence or unacceptable toxicity

What Are the Safety Considerations?

The most common adverse reactions in the adjuvant setting include diarrhea, pruritus, nausea, arthralgia, hypothyroidism, cough, rash, fatigue, influenza-like illness, and weight loss. Pembrolizumab can cause immune-mediated adverse reactions affecting the lungs, colon, liver, endocrine systems, kidneys, and skin. The FDA requires a Boxed Warning for these immune-mediated adverse reactions.

According to trial data, 14% of patients discontinued treatment due to adverse reactions.

How Does This Approval Impact Melanoma Treatment?

The FDA approval established pembrolizumab as a first-line adjuvant option for high-risk Stage III melanoma patients post-surgery. This expanded oncology treatment options beyond interferon and ipilimumab, offering improved efficacy with a different safety profile. The approval positioned Keytruda in competition with nivolumab (Opdivo), which gained adjuvant melanoma approval in December 2017.

What Questions Remain for Future Research?

Ongoing questions include optimal treatment duration, role of combination therapies, biomarkers for patient selection (PD-L1 expression showed benefit across subgroups), and long-term survival outcomes beyond recurrence-free survival. The 5-year follow-up data confirmed sustained RFS benefit, supporting the durability of adjuvant pembrolizumab efficacy.

Frequently Asked Questions

Primary Sources

1. U.S. Food and Drug Administration. FDA approves pembrolizumab for adjuvant treatment of melanoma. February 15, 2019.
2. ClinicalTrials.gov. EORTC 1325-MG/KEYNOTE-054: A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Resected, High-risk Stage II Melanoma (NCT02362594).
3. Eggermont AMM, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378(19):1789-1801.